Great business model: Moderna looks to test Covid-19 “booster” shots a year after initial vaccination
This is very healthy, for every business bank account. Moderna is planning to test a booster shot of its Covid-19 vaccine one year after initial vaccination, “as duration of protection isn't yet known”.
Moderna plans to test a booster shot of its Covid-19 vaccine a year after the initial two-dose immunization, as the duration of protection from the new vaccines is still unclear.
The biotech company plans to start the trial in July, according to a corporate presentation at the JPMorgan Healthcare Conference on Monday. Staff at its clinical trial sites have already started to contact participants in its earlier studies, according to an e-mail shared by one of those people.
“From what we’ve seen so far, I think our expectation is that the vaccination should last you at least a year,” Moderna’s chief medical officer, Dr. Tal Zaks, told investors and analysts at the conference. “To the degree that you need a booster shot, we’ll make a data-based recommendation, and that will require us getting the data.”
The first participants in Moderna’s human clinical trials received their shots in mid-March; a second was given four weeks later. Since the earlier trials tested multiple doses of the vaccine, those on lower doses than the one ultimately authorized — 100 micrograms — would get their booster earlier, while those on 100 micrograms or higher would get their booster at the year mark, according to an e-mail to participants.
The booster being planned now is the same version of the vaccine that’s on the market, but Moderna CEO Stephane Bancel said it may be necessary in the coming years to adjust the vaccine to cover new variants.
“I think this will become a market like flu,” he told CNBC. Moderna has recently started a seasonal flu vaccine program as well.
The booster study for Moderna’s Covid-19 vaccine will evaluate both safety and how much of an immune response an additional shot one year later generates, Bancel said at the conference.
The biotech company plans to start the trial in July, according to a corporate presentation at the JPMorgan Healthcare Conference on Monday. Staff at its clinical trial sites have already started to contact participants in its earlier studies, according to an e-mail shared by one of those people.
“From what we’ve seen so far, I think our expectation is that the vaccination should last you at least a year,” Moderna’s chief medical officer, Dr. Tal Zaks, told investors and analysts at the conference. “To the degree that you need a booster shot, we’ll make a data-based recommendation, and that will require us getting the data.”
The first participants in Moderna’s human clinical trials received their shots in mid-March; a second was given four weeks later. Since the earlier trials tested multiple doses of the vaccine, those on lower doses than the one ultimately authorized — 100 micrograms — would get their booster earlier, while those on 100 micrograms or higher would get their booster at the year mark, according to an e-mail to participants.
The booster being planned now is the same version of the vaccine that’s on the market, but Moderna CEO Stephane Bancel said it may be necessary in the coming years to adjust the vaccine to cover new variants.
“I think this will become a market like flu,” he told CNBC. Moderna has recently started a seasonal flu vaccine program as well.
The booster study for Moderna’s Covid-19 vaccine will evaluate both safety and how much of an immune response an additional shot one year later generates, Bancel said at the conference.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
